Zevra Therapeutics Inc (ZVRA) Stock Analysis
Verdict: BUY
MIPLYFFA's rapid U.S. commercial adoption and $260M cash cushion outweigh the EU regulatory setback, offering strong risk-reward.
Investment score: 66/100
Analysis as of
Is Zevra Therapeutics Inc stock worth reviewing? AI model thesis
The AI model sees Zevra Therapeutics as a high-conviction commercial biotech recovery play. Despite a 27.2% 90-day drawdown triggered by a European regulatory rejection, the underlying US business is accelerating with 95% gross margins and $30.2M quarterly MIPLYFFA sales. Backed by $260.2M in total liquidity and Orange Book patent exclusivity through 2041, the company possesses immense downside protection and significant re-rating potential.
7-factor investment score
- Valuation: 68/100 (weight 20%)
- Financial Health: 92/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 88/100 (weight 10%)
- Risk-Adjusted Return: 65/100 (weight 15%)
Zevra Therapeutics Inc opportunities and risks
What speaks for ZVRA
- MIPLYFFA US Commercial Acceleration in Ultra-Rare Disease
What speaks against ZVRA
- European Regulatory Failure Permanently Limits Global Market Potential
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ZVRA | 10.4x | 4.3x | 6.1x | 95.0% | 42.8% | 5.5% |
| SGP | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.2% |
| COLL | 15.2x | 0.9x | 3.1x | 60.0% | 5.9% | 43.5% |
| LXRX | n/a | 16.3x | n/a | 98.9% | -147.4% | -11.8% |
| Peer median | n/a | 0.9x | n/a | 60.0% | 0.0% | -6.2% |
Frequently asked questions about Zevra Therapeutics Inc (ZVRA)
Is ZVRA stock a good investment?
The cached TradeMates AI model rates Zevra Therapeutics Inc as BUY with an investment score of 66/100. The AI model sees Zevra Therapeutics as a high-conviction commercial biotech recovery play. Despite a 27.2% 90-day drawdown triggered by a European regulatory rejection, the underlying US business is accelerating with 95% gross margins and $30.2M quarterly MIPLYFFA sales. Backed by $260.2M in total liquidity and Orange Book patent exclusivity through 2041, the company possesses immense downside protection and significant re-rating potential. This is algorithmic model output, not personal investment advice.
Is ZVRA stock a buy?
The TradeMates model verdict for ZVRA is BUY with an investment score of 66/100. Treat this as a model signal to review, not a personal buy recommendation.